US 7,572,790 B2
Biphenyl carboxylic amide p38 kinase inhibitors
Nicola Mary Aston, Stevenage (United Kingdom); Paul Bamborough, Stevenage (United Kingdom); Katherine Louise Jones, Stevenage (United Kingdom); Vipulkumar Kantibhai Patel, Stevenage (United Kingdom); Stephen Swanson, Stevenage (United Kingdom); and Ann Louise Walker, Stevenage (United Kingdom)
Assigned to SmithKline Beecham Corporation, Philadelphia, Pa. (US)
Appl. No. 10/551,502
PCT Filed Apr. 07, 2004, PCT No. PCT/EP2004/003774
§ 371(c)(1), (2), (4) Date Jun. 28, 2006,
PCT Pub. No. WO2004/089874, PCT Pub. Date Oct. 21, 2004.
Claims priority of application No. 0308186.6 (GB), filed on Apr. 09, 2003.
Prior Publication US 2007/0129354 A1, Jun. 07, 2007
Int. Cl. A61K 31/54 (2006.01); A61K 31/5377 (2006.01); A61K 31/495 (2006.01); A61K 31/445 (2006.01); A61K 31/426 (2006.01); A61K 31/421 (2006.01); A61K 31/4164 (2006.01); A61K 31/40 (2006.01); A61K 31/165 (2006.01)
U.S. Cl. 514—227.5  [514/237.8; 514/252.12; 514/317; 514/365; 514/374; 514/396; 514/408; 514/602; 514/616; 544/59; 544/162; 544/399; 546/229; 548/577; 564/86; 564/152] 15 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Drawing
wherein
R1 is selected from hydrogen, C1-6alkyl optionally substituted by up to three groups independently selected from C1-6alkoxy, halogen and hydroxy, C2-6alkenyl, C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups, phenyl optionally substituted by up to three groups independently selected from R5 and R6 or heteroaryl optionally substituted by up to three groups independently selected from R5 and R6,
R2 is selected from hydrogen, C1-6alkyl or —(CH2)p—C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups,
or (CH2)mR1 and R2, together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C1-6alkyl groups;
R3 is chloro or methyl;
R4 is the group —NH—CO—R7 or —CO—NH—(CH2)p—R8;
R5 is selected from C1-6alkyl, C1-6alkoxy, —(CH2)p—C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups, —CONR9R10, —NHCOR10, —SO2NHR9, —CH2)qNHSO2R10, halogen, CN, OH, —(CH2)qNR11R12 or trifluoromethyl;
R6 is selected from C1-6alkyl, C1-6alkoxy, halogen, trifluoromethyl or —(CH2)qNR11R12;
R7 is selected from hydrogen, C1-6alkyl, —(CH2)p—C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups, trifluoromethyl, —(CH2)rheteroaryl optionally substituted by R13 and/or R14 or —(CH2)rphenyl optionally substituted by R13 and/or R14;
R8 is selected from hydrogen, C1-6alkyl, C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups, CONHR9, phenyl optionally substituted by R13 and/or R14 or heteroaryl optionally substituted by R13 and/or R14;
R9 and R10 are each independently selected from hydrogen or C1-6alkyl, or
R9 and R10, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R15, wherein the ring is optionally substituted by up to two C1-6alkyl groups;
R11 is selected from hydrogen, C1-6alkyl or —(CH2)p—C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups;
R12 is selected from hydrogen or C1-6alkyl, or
R11 and R12, together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R15;
R13 is selected from C1-6alkyl, C1-6alkoxy, —CH2)p—C3-7cycloalkyl optionally substituted by one or more C1-6alkyl groups, —CONR9R10, —NHCOR10, halogen, CN, —(CH2)qNR11R12, trifluoromethyl, phenyl optionally substituted by one or more R14 groups or heteroaryl optionally substituted by one or more R14 groups;
R14 is selected from C1-6alkyl, C1-6alkoxy, halogen, trifluoromethyl or —NR11R12;
R15 is selected from hydrogen or methyl;
X and Y are each independently selected from hydrogen, methyl or halogen;
Z is selected from —(CH2)sOR16, —(CH2)sNR16R17, —(CH2)sCH2CH2R16, —(CH2)sCOOR16, —(CH2)sCONR16R17, —(CH2)sNHCONR16R17, —(CH2)sSO2R16, —(CH2)sSO2NR16R17 or —(CH2)sNHSO2R16;
R16 is selected from hydrogen, C1-6alkyl optionally substituted by up to two hydroxy groups, —(CH2)tOR18, —(CH2)tNR18R19, —(CH2)tNHSO2R18, —(CH2)tCONR18R19, —(CH2)tCOOR18, —(CH2)theteroaryl optionally substituted by up to two groups independently selected from halogen, C1-6alkyl or oxo, or —(CH2)tphenyl optionally substituted by up to two groups independently selected from halogen, C1-6alkyl or C1-6alkoxy,
R17 is selected from hydrogen or C1-6alkyl, or
R16 and R17, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R15, wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen or C1-6alkyl;
R18 and R19 are each independently selected from hydrogen or C1-6alkyl optionally substituted by up to two hydroxy groups, or
R18 and R19, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R15, wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen or C1-6alkyl;
m is selected from 0, 1, 2, 3 or 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups independently selected from C1-6alkyl or halogen;
n is 1;
p is selected from 0, 1 or 2;
q is selected from 0, 1, 2 or 3;
r is selected from 0 or 1;
s is selected from 0, 1, 2, 3 and 4; and
t is selected from 1,2, 3or 4;
or a pharmaceutically acceptable salt thereof.